.It's an unusually active Friday for biotech IPOs, with Zenas BioPharma, MBX as well as Bicara Rehab...
.Atea Pharmaceuticals' antiviral has actually fallen short an additional COVID-19 trial, yet the bio...
.Neurocrine Biosciences' mental illness program pivot has neglected. The biotech was actually unable...
.Sanofi has actually brought in an overdue entry to the radioligand event, paying one hundred millio...
.After F2G's initial try to receive a new class of antifungal to market was actually hindered due to...
.Moderna has pledged to cut R&D spending by $1.1 billion by 2027. The decision to retract the fin...
.Only four months after Sanofi wager $80 million in beforehand cash on Fulcrum Therapies' losmapimod...
.Cancer cells business Oncternal Rehabs is actually folding all its own professional trials and layi...
.Roche is actually keeping out chances that its injectable weight problems possibility could eventua...
.Novo Nordisk has actually elevated the cover on a period 1 trial of its oral amylin as well as GLP-...